Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 13/20 | 0.68 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.64 |
| ▸ | PTGES | O14684 | 1/20 | 0.64 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.62 |
| ▸ | APLNR | P35414 | 1/20 | 0.59 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27083325 | 0.92 | TAS2R14 (0.60) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL4012164 | 0.88 | TAS2R14 (0.53) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL2109904 | 0.88 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL20594841 | 0.85 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL22501451 | 0.85 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL1888996 | 0.85 | TAS2R14 (0.81) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL2445958 | 0.84 | TAS2R14 (0.82) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL28729777 | 0.84 | TAS2R14 (0.80) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL1893819 | 0.83 | TAS2R14 (0.72) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL24724011 | 0.83 | TAS2R14 (0.62) | TAS2R14CXCR3PTGESTAS2R8CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327452-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | ENANTA PHARM INC (US) | 2024-10-03 | — | — | US | disclosed |
| US-11958879-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230113609-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230041621-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220402966-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2022-12-22 | — | — | US | disclosed |
| CN-115380036-A | SSTR5 antagonists | 卡尔优普公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-4073075-A1 | SSTR5 ANTAGONISTS | Kallyope, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| EP-4069702-A1 | SSTR5 ANTAGONISTS | Kallyope, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-11040998-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2021113368-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-3277286-B1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20200109164-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-10457703-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3277286-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016161003-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHAMRACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289262-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289262-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
| EP-0873311-A1 | TRI-ARYL ETHANE DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-10-28 | — | — | EP | disclosed |
| US-5710170-A | Tri-aryl ethane derivatives as PDE IV inhibitors | MERCK FROSST CANADA, INC. (CA) | 1998-01-20 | — | — | US | disclosed |
| WO-1997022586-A1 | TRI-ARYL ETHANE DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040998-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | TAS2R14 575/4885CXCR3 313/4885PTGES 1341/4885 |
| US-11958879-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | TAS2R14 575/4885CXCR3 313/4885PTGES 1341/4885 |
| US-20230113609-A1 | SSTR5 ANTAGONISTS | SSTR5, GLP1R, GPR119 | TAS2R14 334/4885CXCR3 1587/4885PTGES 2056/4885 |
| US-20220402966-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | TAS2R14 575/4885CXCR3 313/4885PTGES 1341/4885 |
| US-20160289262-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | TAS2R14 575/4885CXCR3 313/4885PTGES 1341/4885 |
| US-20200109164-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | TAS2R14 575/4885CXCR3 313/4885PTGES 1341/4885 |
| US-10457703-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | TAS2R14 575/4885CXCR3 313/4885PTGES 1341/4885 |
| US-20240327452-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | GPBAR1, NR1H4, SLC10A1 | TAS2R14 575/4885CXCR3 313/4885PTGES 1341/4885 |
| US-20230041621-A1 | SSTR5 ANTAGONISTS | SSTR5, GLP1R, GPR119 | TAS2R14 334/4885CXCR3 1587/4885PTGES 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.